Autopsy report · NCT00399893

Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)

“Inadequate recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 3 years 9 months before it stopped.
• 5 participants enrolled.
• Results were posted on the registry 3 years 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Duke University

Sponsor type

University, hospital or other

Conditions

Prader-Willi Syndrome

Interventions

Octreotide; Placebo

Participants

5

Sites

1

Countries

United States

Trials that died the same way

• Use of Patient-Controlled Analgesia in Acute Pancreatitis
  “inadequate recruitment despite efforts” (96% match in meaning)
• Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation
  “lacking recruitment” (95% match in meaning)
• Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma
  “lack of recruitment” (93% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.